humans can mount a successful protective response against simpler retrovrwuses, whereas birds cannot. Thus, humans might be able to mount a successful protective response to infection with a simpler HIV-1. As a model, a simpler bovine leukemia virus which is capable of replicating has been constructed; a simpler HIV-1 could be constructed in a similar fashion. I suggest that such a simpler HIV-1 would be a safe and effective vaccine against HIV-1.
There is as yet no safe and effective vaccine against human immunodeficiency type 1 (HIV-1), the causative agent of AIDS (1) (2) (3) (4) . Probably the primary reason for this failure is that the nature of a protective immune response against HIV-1 is not known. Clearly, the usual immune response in persons after infection with HIV-1 is not sufficiently protective. In this article, I shall argue that evolution has provided a natural experiment that might direct us to a safe and effective vaccine against HIV-1.
HIV-1 is a lentiretrovirus, one of the more complex retroviruses (5); Hilleman (2) calls it an extraordinary virus. As a more complex retrovirus, HIV-1, like human T-cell leukemia virus type I (HTLV-I), bovine leukemia virus (BLV),-and human spumaretrovirus (HSRV), differs from simpler retroviruses in having many genes in addition to gag, pol, and env, which are common to all retroviruses.
All retroviruses contain the gag, pol, and env genes and the cis-acting sequences acted on by the Gag and Pol proteins, as well as the sequences involved in the control oftranscription, splicing, and polyadenylylation. In the case of simpler retroviruses, such as murine leukemia virus, the processes of viral transcription, splicing, and polyadenylylation are controlled by cellular proteins. The additional genes in more complex retroviruses code for proteins that act with cellular proteins to control transcription, splicing, and polyadenylylation and enable more complex retroviruses to have morecomplex replication cycles (5, 6) .
Simpler retroviruses were first found in chickens and have been much studied in chickens and mice. They are also found in vipers, fish, and cats, and there are even a few isolates from monkeys (7) . Gibbon ape leukemia virus is a murine leukemia virus-related simpler retrovirus, and Mason-Pfizer monkey virus is a primate type D simpler retrovirus. Study of the human genome indicates that in the past many simpler retroviruses infected our ancestors, as shown by the relic proviruses in human DNA (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) .
More complex retroviruses were first isolated in horses (equine infectious anemia virus). Since then they have been isolated from many other mammals, including at least five from humans (HIV-1, HIV-2, HTLV-I, HTLV-II, and HSRV). So (17) describe such a mechanism in human serum for controlling simpler retroviruses.] The presence of genomes of simpler retroviruses in the human genome (endogenous viruses) indicates that, earlier in evolution, ancestors of present-day humans were successfully infected by such simpler retroviruses (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) .
A conclusion from this line of reasoning is that present-day humans are able to mount a protective response against simpler retroviruses. Since HIV-1 is a more complex retrovirus, this conclusion does not yet help direct us toward methods for making a safe and effective HIV-1 vaccine. However, if we were able to construct a simpler retrovirus that expressed only the Gag, Pol, and Env proteins of HIV-1, this virus should induce in humans a protective response against itself, the simpler HIV-1. If such a protective response occurs against infection by a simpler HIV-1, I further propose that this protective response would protect against wild-type HIV-1 infection, and thus that the simpler HIV-1 would form an effective vaccine against HIV-1, either as a live "attenuated" virus or as an inactivated virus.
Such a simpler HIV-1 is fundamentally different from vector-or DNA-expressed HIV-1 structural proteins, which cannot replicate in the vaccine recipient (18) (19) (20) (21) (26) . Assembly of Gag, Pol, and Env proteins into virions appears to proceed in the absence of accessory proteins (18) (19) (20) (21) (22) . If not, Vif or other accessory proteins may also need to be present. They could be added back into the constructs.
The utility of such constructs could first be validated in simpler HIV-1/chimpanzee and simian immunodeficiency virus/macaque model systems (see refs. 4 and 27). If there is concern about insertional activation increasing the possibility of leukemia, a killed vaccine made from the simpler HIV-1 could first be tested. However, if it appeared that only a live virus vaccine would be adequate to prevent HIV-1 infection and insertional activation by the simpler HIV-1 appeared to be a problem, the simpler HIV-1 could be further crippled by mutating promoter and enhancer sequences or adding a gene that can be selected against (a suicide gene) expressed from a picornaviral internal ribosome entry site (28) (29) (30) .
The seriousness of the AIDS pandemic and the so-far low effectiveness of other immunodeficiency virus vaccines, except possibly nef simian immunodeficiency virus (27) 
